D-0361-2025 Class II Ongoing
FDA drug recall D-0361-2025 was initiated by Zydus Pharmaceuticals (USA) Inc on Apr 3, 2025 and is designated Class II. Reason for recall: CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit The recall status is ongoing. Affected quantity: 3144 bottles, pack size: 100's Count.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 16, 2025
- Initiation Date
- Apr 3, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3144 bottles, pack size: 100's Count
Product description
chlorproMAZINE Hydrochloride Tablets, USP 10 mg, Rx Only, 100 Tablets bottles, Manufactured by: Zydus Lifesciences Ltd., Baddi, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1129-1
Reason for recall
CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit
Distribution pattern
Nationwide within U.S - MS, AL, TN, VT, OH, ND, MN, WI, SC, AR, FL, IN, LA, NJ, AZ, TX, KY and PA
Code information
Lot #: Z400069, Exp.: 12/31/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0361-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026